Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three

Executive Summary

With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total of five IPOs – three in January and two in March – and several more are in the queue.

Advertisement

Related Content

Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine
IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start
Tocagen Aims Double Barrels At Glioma
Takeda Targets Severe Epilepsies In Ovid Alliance
Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
Venture Funding Deals: Innovent Sets Financing Record In China
Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels
UK's Verona £44.7m Capital Raising To Be Followed By NASDAQ Listing
Let's Make a Deal: Levin's Ovid Raises $75m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098649

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel